Investigation of the effects of omega-3 on immune system in patients with thyroid cancer under the treatment with radioiodine

Investigation of the effects of omega-3 fatty acids on Th1/Th2/Th9/Th17/Th22 cytokines in patients with differentiated thyroid cancer under the treatment with radioiodine

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220104053622N1

Enrollment

Registered

2022-02-05

Start date

2020-02-09

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer. cancer

Interventions

Intervention 1: Intervention group: Patients who received omega-3 for 30 days before RAI therapy.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Involving with differentiated thyroid cancer Adult patients Total or near-total thyroidectomy Planned for radioiodine ablation with 150 mCi or 100 mCi

Exclusion criteria

Exclusion criteria: Patients who will be received radioiodine at doses higher than 150 mCi Patients who were previously received radioiodine Patients who had taken omega-3 or other supplements before the study Patients who had undergone a second thyroid surgery Patients who have other cancers Patients who have concurrent chronic inflammatory disease Patients who have autoimmune disease or other cancers

Design outcomes

Primary

Measure	Time frame
Cytokine change. Timepoint: 30 days before RAI, Just before RAI, 7 & 30 days after RAI. Method of measurement: Cytometric bead-based assay.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shirin Farjadian

Shiraz University of Medical Sciences

farjadsh@sums.ac.ir+98 71 3235 2575

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026